- Home
- AIRT vs ONCY Comparison
AIRT vs ONCY Comparison
Compare AIRT & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ONCY
- Stock Information
- Founded
- AIRT 1980
- ONCY 1998
- Country
- AIRT United States
- ONCY Canada
- Employees
- AIRT N/A
- ONCY N/A
- Industry
- AIRT Air Freight/Delivery Services
- ONCY Pharmaceuticals and Biotechnology
- Sector
- AIRT Consumer Discretionary
- ONCY Health Care
- Exchange
- AIRT Nasdaq
- ONCY Nasdaq
- Market Cap
- AIRT 53.2M
- ONCY 49.1M
- IPO Year
- AIRT N/A
- ONCY 1999
- Fundamental
- Price
- AIRT $21.13
- ONCY $0.79
- Analyst Decision
- AIRT
- ONCY Strong Buy
- Analyst Count
- AIRT 0
- ONCY 4
- Target Price
- AIRT N/A
- ONCY $4.33
- AVG Volume (30 Days)
- AIRT 2.7K
- ONCY 1.2M
- Earning Date
- AIRT 06-27-2025
- ONCY 07-31-2025
- Dividend Yield
- AIRT N/A
- ONCY N/A
- EPS Growth
- AIRT N/A
- ONCY N/A
- EPS
- AIRT N/A
- ONCY N/A
- Revenue
- AIRT $291,850,000.00
- ONCY N/A
- Revenue This Year
- AIRT N/A
- ONCY N/A
- Revenue Next Year
- AIRT N/A
- ONCY N/A
- P/E Ratio
- AIRT N/A
- ONCY N/A
- Revenue Growth
- AIRT 1.75
- ONCY N/A
- 52 Week Low
- AIRT $14.56
- ONCY $0.33
- 52 Week High
- AIRT $30.60
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- AIRT 54.46
- ONCY 70.92
- Support Level
- AIRT $18.86
- ONCY $0.71
- Resistance Level
- AIRT $22.50
- ONCY $0.81
- Average True Range (ATR)
- AIRT 1.01
- ONCY 0.08
- MACD
- AIRT -0.09
- ONCY 0.01
- Stochastic Oscillator
- AIRT 42.31
- ONCY 91.15
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.